Genmab — Juli 2018
-
At AQR reducerer er vel også en positiv trigger.
-
Teknisk er vi også gået i bekræftet uptrend igen med brud
af 1.020. -
Det er jeg tirsdag med opsamling på bla. Genmab.
-
the NICE appraisal document https://www.nice.org.uk/guidance/GID-TA10174/documents/appraisal-consultation-document
-
NICE: there was a statistically significant
(p<0.0001) increase in progression-free survival with daratumumab plus
bortezomib and dexamethasone (median survival 26 months) compared
with bortezomib plus dexamethasone (median survival 8 months; hazard
ratio [HR] 0.23, 95% confidence interval [CI] 0.16 to 0.33), after a median
follow-up of 27 months (pre-specified interim analysis). -
-
Genmab, Immatics Launch Up-to-$2.8B+ Cancer Immunotherapy Partnership https://www.genengnews.com/gen-news-highlights/genmab-immatics-launch-up-to-28b-cancer-immunotherapy-partnership/81256019
-
usefull tweet EPVantage https://twitter.com/EPVantage/status/1017421620305170432
-
Collaboration Worth Over €1Bn Could Give Rise to New Cancer Immunotherapies - labiotech - https://labiotech.eu/genmab-immatics-cancer-immunotherapy/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind